Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 昊海生科 |
|---|---|
| Other Market Stock Code | 688366 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Haohai Biotec |
|---|---|
| Stock Code | 06826 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 專注於研發、生產及銷售醫用可吸收生物材料,產品應用於骨科、防黏連及止血、眼科和創面護理及組織填充等治療領域。 |
| Listing Date | 2015-04-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市長寧區虹橋路1386號文廣大廈23樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | 3healthcare.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 59.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 100 shares |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2015-04-20 to 2015-04-23 |
| Global Offering Shares | 40,000,000 shares |
| HK Public Offer Shares (Initial) | 4,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | 40,000lots (Pool A20,000lots,Pool B20,000lots) |
| International Placing Shares (Initial) | 36,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 160,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 4.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 2,360,000,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 661.6M |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣183.6百萬元 |
| Period-End Cash Balance | 人民幣181.3百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2012 | 2013 | 2014 |
|---|---|---|---|
| Revenue | 303,065 | 401,088 | 515,940 |
| Cost of sales | -50,313 | -54,836 | -65,883 |
| Gross profit | 252,752 | 346,252 | 450,057 |
| Other income and gains, net | 10,835 | 23,677 | 30,764 |
| Selling and distribution expenses | -72,537 | -143,315 | -187,191 |
| Administrative expenses | -36,272 | -34,221 | -48,960 |
| Profit before tax | 133,432 | 166,467 | 215,616 |
| Income tax expense | -19,490 | -24,946 | -32,034 |
| Profit for the year | 113,942 | 141,521 | 183,582 |
| Profit attributable to owners | 113,942 | 141,521 | 183,582 |
Balance Sheet
| Item | 2012 | 2013 | 2014 |
|---|---|---|---|
| Cash and cash equivalents | 160,814 | 197,137 | 181,341 |
| Trade and bills receivables | 29,480 | 43,820 | 62,443 |
| Inventories | 40,864 | 42,604 | 76,364 |
| Total current assets | 245,287 | 297,448 | 347,355 |
| Total assets | 448,037 | 621,178 | 751,903 |
| Total current liabilities | 54,702 | 76,128 | 139,239 |
| Total liabilities | 58,980 | 90,600 | 157,743 |
| Total equity | 389,057 | 530,578 | 594,160 |
| Equity attributable to owners | 389,057 | 530,578 | 594,160 |
Cash Flow Statement
| Item | 2012 | 2013 | 2014 |
|---|---|---|---|
| Net cash from operating activities | 118,420 | 146,906 | 141,993 |
| Net cash from investing activities | -84,293 | -111,249 | -88,151 |
| Net cash from financing activities | 0 | 0 | -70,320 |
| Net increase in cash | 34,127 | 35,657 | -16,478 |
| Depreciation of PP&E | 11,559 | 9,562 | 20,917 |
| Amortisation of intangible assets | 1,378 | 2,389 | 1,186 |
| Purchase of PP&E | -64,626 | -124,361 | -93,544 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 58.4 |
|---|---|
| First Day Open | HK$ 54.0 |
| First Day Change | -1.01% |
| First Day Volume | 18649000.0 |
| First Day Turnover | 1065410000.0 |
| Use of Proceeds | 1、約25%或約563百萬港元,將用于建設上海利康瑞的新生產線,包括動物源纖維蛋白封閉劑產品及醫用生物材料的新生產設施,以應付對產品不斷增長的需求;
2、約25%或約563百萬港元,將用于選擇性收購專注于我們目標治療領域內具高增長潛能產品及對我們現有產品組合具互補性產品的合適生物醫藥或醫用生物材料公司或資產。截至最后實際可行日期,我們尚未物色到任何可予收購的目標;
3、約18%的所得款項凈額,或約405百萬港元,將用于購買新生產設備,以及翻新及改造昊海生物設施;
4、約13%或約293百萬港元,將用于資助在研產品(包括溫敏性幾丁糖產品及新一代交聯透明質酸鈉產品)的研發活動及臨床應用;
5、約9%或約203百萬港元,將用于招聘更多營銷及銷售人員以擴大我們的銷售及營銷網絡,及將我們成功開發的在研產品進行商業投產,以及提升營銷及促銷活動水平;
6、約10%或約225百萬港元,將用作營運資金及一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
UBS Securities Hong Kong Limited CE BIN466
Overall Coordinators (1)
UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Dragon Billion China Master Fund | 193,697,000 HKD | — | 2.05% | — | 6 months | 2015-10-30 |
| 2 | 方圆投资管理(香港)有限公司 | 232,460,000 HKD | — | 2.46% | — | 6 months | 2015-10-30 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 侯永泰 | — |
| Company Secretary | 黃平、趙明璟 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 蔣偉及游捷(配偶)合共持有75,600,000股,佔全球發售後本公司全部股本約47.25%;樓國梁持有10,000,000股,佔約6.25%。 |
|---|




